Fusion Protein Vaccines Targeting Two Tumor Antigens Generate Synergistic Anti-Tumor Effects

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Cheng, Wen Fang ^a   Chang, Ming Cheng ^a   Sun, Wei Zen ^a   Jen, Yu Wei ^a   Liao, Chao Wei ^b   Chen, Yun Yuan ^a   Chen, Chi An ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b ANIMAL TECHNOLOGY INSTITUTE TAIWAN   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; E6 TUMOR ANTIGEN; E7 TUMOR ANTIGEN; FUSION PROTEIN VACCINE; GAMMA INTERFERON; PEPTIDE VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTECTION; PROTEIN DEPLETION; SOLID TUMOR; TUMOR IMMUNITY; TUMOR VOLUME; WART VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CANCER VACCINES; CYTOKINES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84884162998     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071216     Document Type: Article

References (36)

1. International Agency for Research on Cancer (1995) Monograph on cancer Human papillomavirus. Geneva, Switzerland: World Health Organization.
2. zur Hausen H, (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184: 9-13. doi:10.1016/0042-6822(91)90816-T. PubMed: 1651607.
3. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, et al. (2007) Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 79: 328-337. PubMed: 1310805.
4. Yasumoto S, Burkhardt AL, Doniger J, DiPaolo JA, (1986) Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J Virol 57: 572-577. PubMed: 3003388.
5. Nasseri M, Gage JR, Lorincz A, Wettstein FO, (1991) Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7. Virology 184: 131-140. doi:10.1016/0042-6822(91)90829-Z. PubMed: 1651587.
6. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, et al. (1985) Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314: 111-114. doi:10.1038/314111a0. PubMed: 2983228.
7. Howley PM, (1991) Role of the human papillomaviruses in human cancer. Cancer Res 51: 5019-5022. PubMed: 1653110.
8. Cheng WF, Lee CN, Chang MC, Su YN, Chen CA, et al. (2005) Antigen-Specific CD8(+) T Lymphocytes Generated from a DNA Vaccine Control Tumors Through the Fas-FasL Pathway. Mol Ther 12: 960-968. doi:10.1016/j.ymthe.2005.04.020. PubMed: 15979942.
9. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, et al. (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4: 1281-1286. doi:10.1038/3266. PubMed: 9809552.
10. Cheng WF, Lee CN, Su YN, Chang MC, Hsiao WC, et al. (2005) Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology 115: 136-149. doi:10.1111/j.1365-2567.2005.02126.x. PubMed: 15819706.
11. Chen CH, Wu TC, (1998) Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 5: 231-252. doi:10.1007/BF02255855. PubMed: 9691216.
12. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, et al. (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317. PubMed: 10361129.
13. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM, (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679. doi:10.1016/S1074-7613(00)80066-7. PubMed: 10403642.
14. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, et al. (2003) Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39: 70-77. doi:10.1016/S0959-8049(02)00479-3. PubMed: 12504661.
15. Liao CW, Chen CA, Lee CN, Su YN, Chang MC, et al. (2005) Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 65: 9089-9098. doi:10.1158/0008-5472.CAN-05-0958. PubMed: 16204084.
16. Hsieh CY, Chen CA, Huang CY, Chang MC, Lee CN, et al. (2007) IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. Mol Ther 15: 1890-1897. doi:10.1038/sj.mt.6300243. PubMed: 17609658.
17. Cheng WF, Chang MC, Sun WZ, Lee CN, Lin HW, et al. (2008) Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. Gene Ther 15: 1007-1016. doi:10.1038/gt.2008.25. PubMed: 18356819.
18. Cheng WF, Hung CF, Lee CN, Su YN, Chang MC, et al. (2004) Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. Eur J Immunol 34: 1892-1900. doi:10.1002/eji.200424877. PubMed: 15214037.
19. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, et al. (2001) Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 12: 235-252. doi:10.1089/10430340150218387. PubMed: 11177561.
20. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, et al. (2002) Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 13: 553-568. doi:10.1089/10430340252809847. PubMed: 11874633.
21. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, et al. (2000) Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18: 3964-3973. PubMed: 11099326.
22. Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, et al. (2004) Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 27: 124-135. doi:10.1097/00002371-200403000-00006. PubMed: 14770084.
23. Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, et al. (2003) A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 171: 219-225. PubMed: 12817001.
24. Huang CY, Chen CA, Lee CN, Chang MC, Su YN, et al. (2007) DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecol Oncol 107: 404-412. doi:10.1016/j.ygyno.2007.06.031. PubMed: 17905417.
25. Peng S, Ji H, Trimble C, He L, Tsai YC, et al. (2004) Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 78: 8468-8476. doi:10.1128/JVI.78.16.8468-8476.2004. PubMed: 15280455.
26. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, et al. (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26. PubMed: 8548765.
27. Chen CA, Chang MC, Sun WZ, Chen YL, Chiang YC, et al. (2009) Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects. Gene Ther 16: 776-787. doi:10.1038/gt.2009.31. PubMed: 19357714.
28. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, et al. (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: 669-678. doi:10.1172/JCI12346. PubMed: 11544272.
29. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, et al. (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242-2249. doi:10.1002/eji.1830230929. PubMed: 7690326.
30. Cheng WF, Chen LK, Chen CA, Chang MC, Hsiao PN, et al. (2006) Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis. Mol Ther 13: 203-210. doi:10.1016/j.ymthe.2006.08.601. PubMed: 16140583.
31. Fominaya J, Uherek C, Wels W, (1998) A chimeric fusion protein containing transforming growth factor-alpha mediates gene transfer via binding to the EGF receptor. Gene Ther 5: 521-530. doi:10.1038/sj.gt.3300614. PubMed: 9614577.
32. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, et al. (2002) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med, 18([MedlinePgn:]) PubMed: 22842478.
33. Hung CF, Hsu KF, Cheng WF, Chai CY, He L, et al. (2001) Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 61: 1080-1088. PubMed: 11221836.
34. Feltkamp MC, Vierboom MP, Toes RE, Ossendorp F, ter Schegget J, et al. (1995) Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization. Immunol Lett 47: 1-8. doi:10.1016/0165-2478(95)00052-7. PubMed: 8537084.
35. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, et al. (2010) Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 18: 1233-1243. doi:10.1038/mt.2010.34. PubMed: 20372107.
36. Nichols WW, Ledwith BJ, Manam SV, Troilo PJ, (1995) Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 772: 30-39. doi:10.1111/j.1749-6632.1995.tb44729.x. PubMed: 8546411.